Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company
will be participating in the following investor conferences during March
2010.
-
The RBC Capital Markets Healthcare Conference
New
York, NY
March 2, 2010
Biodefense Panel
Discussion
3:35 PM Eastern
[This will be an
audio-only webcast.]
-
The Cowen & Company 30th Annual
Healthcare Conference
Boston, MA
March 8,
2010
Corporate Overview Presentation
1:45 PM
Eastern
[There will be a full webcast with slides that will
include discussion of the Company’s business activities, financial
outlook and current news.]
Both webcasts will be accessible from the Emergent website www.emergentbiosolutions.com
under "Investors”.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the
development, manufacture and commercialization of vaccines and
therapeutics that assist the body’s immune system to prevent or treat
disease. Emergent’s marketed product, BioThrax® (Anthrax
Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and
Drug Administration for the prevention of anthrax infection. Emergent’s
product pipeline targets infectious diseases and includes programs
focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional
information may be found at www.emergentbiosolutions.com.
